Nature Medicine

ISSN: 1078-8956

Journal Home

Journal Guideline

Nature Medicine Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine on the basis of its originality, timeliness, interdisciplinary interest and impact on improving human health. Nature Medicine also publishes commissioned content, including News, Reviews and Perspectives, aimed at contextualizing the latest advances in translational and clinical research to reach a wide audience of M.D. and Ph.D. readers. It has an SJR impact factor of 19,536.

Nature Medicine focuses its scope in these topics and keywords: cell, cells, t, receptor, correction, autoimmune, dna, drug, therapies, tissue, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Non Open Access

Type of publications:

Publication frecuency: Monthly


Nature Medicine


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Aims and Scope

cell, cells, t, receptor, correction, autoimmune, dna, drug, therapies, tissue, tumor, chromosome, hiv, tau, cancer, induced, human, target, sustains, efficacy, essential, fas, gene, imaging, immune, dendritic, inflammation, liver, responses, disease,

Best articles

...and political issue

View more

An array of possibilities for multiple sclerosis

View more

Angiogenesis inhibitors revised and revived at AACR

View more

Animal research stance spells knight-mare for Blakemore

View more

At the Helm: A Laboratory Navigator

View more

Balancing risks on the backs of the poor

View more

Can a killer be arrested?

View more

Can WHO provide guidance on HIV drugs for developing countries?

View more

Cell-switching and kissing

View more

Ceramide lances the lungs

View more

Complement-specific antibodies: Designing novel anti-inflammatories

View more

Compromise for Australian ES cell research

View more

Conflicts of interest

View more

Corticosteroids and cardioprotection

View more

Cross-species infection: No news is good news?

View more

Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice

View more

Emerging opportunities and career paths for the young physician-scientist

View more

EMSY, a BRCA-2 partner in crime

View more

Erratum: Corrigendum: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

View more

Erratum: Corrigendum: Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates

View more

Erratum: Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation

View more

Erratum: Not just research tools - proteasome inhibitors offer therapeutic promise

View more

FasL, leukocytes and vascular modeling

View more

FDA criticized for dangerous leniency

View more


No comments ... Be the first to comment!